


  // export const genomic_characterization_card =  {
  //   title: 'Genomic and functional characterization',
  //   subtitle: 'Over 150k genomic features and dependencies for hematopoietic and solid tumor cell lines covering 80 subtypes.',
  //   image: '2025 PRISM-website-graphics-about-01.png',
  //   action: {
  //     text: 'Learn more',
  //     url: '/screening/cell-line-collection'
  //   }
  // }
  // export const multiple_screening_offerings_card =  {
  //   title: 'Multiple screening offerings',
  //   subtitle: 'Small molecules, combinations, antibody-drug conjugates, antibodies, and cytokines at multiple time points.',
  //   image: '2025 PRISM-website-graphics-about-02.png',
  //   action: {
  //     text: 'Learn more',
  //       url: '/screening/assays'
  //   }
  // }
  export const predictive_modeling_card =  {
    title: 'Predictive modeling to identify patient population and targets',
    subtitle: 'Univariate and multivariate predictive models to compare the viability profile of your drug with genomic features.',
    image: '2025 PRISM-website-graphics-about-03.png',
    action: {
      text: 'Learn more',
      url: '/screening/data'
    }
  }
  // export const secure_data_portal_card =  {
  //   title: 'Secure data portal',
  //   subtitle: 'Securely browse and discover insights from your screening results with interactive visualizations.',
  //   image: `2025 PRISM-website-graphics-about-04.png`,
  //   action: {
  //     text: 'Learn more',
  //     url: 'theprismlab.org/portal'
  //   }
  // }

  export const cell_lines_card =  {
    title: '900+ pooled and barcoded cell lines',
    subtitle: 'Hematopoietic and solid tumor, covering 80 cancer subtypes',
    image: '2025 PRISM Graphics - cell lines.png',
    action: {
      text: 'Learn more',
      url: '/screening/cell-line-collection',
      target: '_self'
    }
  }
export const test_agents_card =  {
  title: 'Multiple screening offerings',
  subtitle: 'Small molecules, combinations, antibody-drug conjugates, antibodies, and cytokines at multiple time points.',
  image: '2025 PRISM Graphics - test agents.png',
  action: {
    text: 'Learn more',
    url: '/screening/assay',
    target: '_self'
  }
  }
  export const viability_features_card =  {
    title: 'Viability profile and genomic characterization',
    subtitle: 'Generate univariate and multivariate predictive models comparing PRISM viability profile with Dependency Map features',
    image: '2025 PRISM Graphics - viability-features.png',
    action: {
      text: 'Learn more',
      url: 'https://depmap.org/portal/',
      target: '_blank'
    }
  }
  export const discover_card =  {
    title: 'Identify target and patient population of your drug',
    subtitle: 'Confirm hypothesis and establish biomarkers of sensitivity and resistance',
    image: '2025 PRISM Graphics - discover.png',
    action: {
      text: 'Learn more',
      url: '/screening/data',
      target: '_self'
    }
  }

export const our_technology_cards = () => {
  return [
    cell_lines_card,
    test_agents_card,
    viability_features_card,
    discover_card
  ]
}

export const prism_impact_cards = () => {
    return [
        {
            value: "150+",
            caption: "Academic and industry partners"
        },
        {
            value: "7,000+",
            caption: "Collaborator compounds screened"
        },
        {
            value: "40+",
            caption: "Publications in high-impact journals"
        }
    ]

}

export const testimonial_cards = () => {
    return [
        {
            text: "I would encourage anyone in the oncology drug development space to take advantage of... the seamless integration of the generated drug-sensitivity data (900+ cell lines) with the Broadâ€™s DepMap multi-omic annotation.",
            name: "Florian Muller",
            title: "Head of Chemistry",
            company: "Lindonlight Collective"
        },
        {
            text: "The true value of PRISM lies in its ability to generate high-throughput data incredibly cost-effectively. The user-friendly, auto-generated reports with built-in analytics supply invaluable insights, streamlining our research process.",
            name: "Discovery Oncology Scientist",
            title: "Fortune 500",
            company: "Pharmaceutical Company"
        }
        
    ]
}